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Background: Tobacco consumption is the most preventable cause of morbidity-mortality in the world. One aspect
of smoking cessation that merits in-depth study is the use of an application designed for smartphones (app), as a
supportive element that could assist younger smokers in their efforts to quit. To assess the efficacy of an
intervention that includes the assistance of a smoking cessation smartphone application targeted to young people
aged 18 to 30 years who are motivated to stop smoking.
Methods/design: Cluster randomised clinical trial. Setting: Primary Health Care centres (PHCCs) in Catalonia.
Analyses based on intention to treat. Participants: motivated smokers of 10 or more cigarettes per day, aged 18 to
30 years, consulting PHCCs for any reason and who provide written informed consent to participate in the trial.
Intervention group will receive a 6-month smoking cessation programme that implements recommendations of a
Clinical Practice Guideline, complemented with a smartphone app designed specifically for this programme. Control
group will receive the usual care. The outcome measure will be abstinence at 12 months confirmed by exhaled-air
carbon monoxide concentration of at least 10 parts per million at each control test.
Discussion: To our knowledge this is the first randomised controlled trial of a programme comparing the efficacy
of usual care with a smoking cessation intervention involving a mobile app. If effective, the modality could offer a
universal public health management approach to this common health concern.
Trial registration: NCT01734421
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Tobacco consumption is the most preventable cause of
morbidity-mortality in the world. Although the preva-
lence of tobacco use among adolescents and young
adults in Europe has decreased in recent years, tobacco
use continues to be a major health problem among
young people with a lower educational level. According
to, data from ESCA 2011, 30.6% of boys and 34.1% of
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distribution, and reproduction in any mediumMany adolescent and young adult smokers want to
stop smoking and report frequent attempts to quit [1].
Valdivieso et al. [2] recently reported high interest in
smoking cessation (67%) among young people who were
habitual smokers and who frequently expressed the
difficulty of maintaining abstinence despite repeated
attempts.
Primary health care has an essential role in smoking
cessation. Results of a randomized clinical trial in
Spain indicate that a smoking cessation intervention
was effective in the adult population, with 8.1% of the
intervention group participants reporting continued
abstinence at one year, compared to 5.8% in the control
group (p<0.014) [3].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of a structured smoking cessation intervention directed
at young people. One aspect of smoking cessation that
merits in-depth study is the potential usefulness of new
technologies, in particular the use of an application
designed for smartphones (app), as a supportive element
that could assist younger smokers in their efforts to quit.
New technologies –and specifically a targeted app-- offer
three benefits that can be useful for this purpose: First,
they reach people “where they are”, i.e. there is no need
to go to any specific place to receive support services.
Second, they promote interactivity, opening new chan-
nels of communication between patients and “experts”.
And third, they provide instant access to information
and assistance. Therefore, it seems logical to hypothesize
that a smartphone app will be a useful tool to offer add-
itional support when a young adult wants to stop smok-
ing [4].
Some efforts have already been made in this direction.
Clinical trials have evaluated the effectiveness of smok-
ing cessation interventions in adolescents and young
people that made use of text messages (SMS), with sig-
nificantly better results than in the control group (9% vs.
4% abstinence) [5,6]. A recent review by Cochrane [7] of
the effectiveness of smoking cessation interventions that
use mobile telephones concludes that further studies are
needed to determine whether these technologies will as-
sist in smoking cessation efforts. Of particular interest
for clinical practice, a programme of text messages sent
to mobile phones was effective in the short term (six
weeks) and a combined programme of Internet and mo-
bile phone messages up to 12 months.
According to a study by Fundación Telefónica (the
foundation associated with Spain’s national telephone
company), the number of “smartphones” (mobile phones
with an advanced operating system such as Android or
iOS) sold in the second trimester of 2011 exceeded for
the first time the number of personal computers sold
(107 million smartphones, compared to 85 million per-
sonal computers). In 2009, more than two thirds of the
world’s population had mobile phone access and more
than 4.2 billion text messages were sent [4]. We would
point out that the youngest segment of the population is
most likely to include new technologies in their everyday
lives. This behaviour pattern is repeated in patterns of
Internet access using mobile phones and 3G technolo-
gies, reaching 26% market penetration among young
people in Spain --more than twice the European average
for this population [4].
Parallel to the growth of smartphone devices, a series
of apps have been developed with the objective of pro-
viding information and support concerning social and
medical problems [8]. The world market for medical
apps for smartphones and tablets multiplied seven-foldin 2011 alone, reaching a total of US$718 million,
according to a market analysis by the American firm
research2guidance [9]. At present, these apps are being
used as instruments of patient education and support
and are also helpful to healthcare professionals [10].
Nonetheless, the market for health care apps is very
fragmented; many are designed for very specific contexts
or low-incidence diseases. To our knowledge, no ran-
domized studies have assessed the effectiveness of
smoking cessation attempts in young people motivated
to stop smoking using a smartphone app.
The objective of the present study is to evaluate the ef-
ficacy of an intervention that incorporates a smartphone
app specifically designed to reduce the prevalence of




This project will be developed in two phases, first the
design and development of the specific app, followed by
a randomized, clustered clinical trial aimed at assessing
the efficacy of the smartphone app. The unit of ran-
domization will be the primary care centres of Catalonia,
which will assess the effectiveness of the app in achiev-
ing smoking cessation among motivated young smokers.
Participants
Selection of participating primary care centres
Participation by primary care centres will be totally vol-
untary. At the beginning of the study a personalized
letter will be sent to the attention of the centre adminis-
trators, requesting their collaboration and providing a
copy of the study protocol. Within two weeks, the ad-
ministrators will be contacted by telephone to confirm
their participation. Each centre that agrees to participate
will be randomized to the intervention or control group
and a visit will be scheduled to inform the participating
primary care physicians and nurses about the study.
Randomisation
The unit of randomisation will be the primary care
centre, stratified according to urban/rural location and
number of participating professionals to ensure compar-
ability between the study groups, and then assigned 1:1
to the intervention or control group. Randomisation will
use the Epidat 3.0 programme.
Blinding
Given the nature of the intervention, it is impossible to
mask the participants or professionals to the study group
assignments. However, data analysis will be blinded to
any potential identifiers.
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a) Young adults aged 18 to 30 years who smoke at least
10 cigarettes per day; b) availability of the patient’s clin-
ical history in the primary care centre; c) access to a
smartphone device that meets the app requirements; d)
access to an Internet data connection; and e) normal to
high motivation to stop smoking on the Richmond test
(score of 5 or higher).
Patient exclusion criteria
a) Addiction to other psychoactive substances; b) any
baseline psychotic disease; c) use of a mobile device that
does not comply with the app requirements; d) smokers
with low motivation to stop smoking on the Richmond
test (score of 4 or lower).Figure 1 Flowchart: randomisation of centres, and sampling and monIntervention
During the recruitment period, or until the required
quota of patients is reached, the family doctor and/or
primary care nurse will invite patients aged 18 to 30
years who smoke 10 or more cigarettes per day to par-
ticipate in the study. If the patient is eligible for inclu-
sion and agrees to participate, informed consent will be
requested (Figure 1). After signing informed consent, the
participant’s demographic data will be collected and the
study questionnaire will be administered (Fageström &
Richmond). During this visit (visit 0) smokers with mod-
erate motivation to stop smoking (Richmond score of 5–
6) will be invited to schedule a second appointment to
attempt to increase their motivation. For highly moti-
vated participants (Richmond score of 7–10) a “quit day”itoring of patients.
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and they will be invited to schedule an appointment for
the day before their D-Day.
At the pre-D-day appointment, smokers will begin their
smoking cessation plan according to the clinical practice
guidelines of the Catalan Health Institute. Participants ran-
domized to the intervention group will receive the smart-
phone app, along with an explanation of how to use it to
support their smoking cessation plan.
Follow-up and treatment for participants in both the
intervention and control groups will follow the clinical
practice guidelines. Participants who do not attend follow-
up appointments will be telephoned, and will be considered
relapsed as of that point.
Development of the mobile app
The app we are designing is included in what are called
serious games, half games or healthy games. These
types of apps have begun to gain recognition as power-
ful learning tools [8], since they offer those who play
the opportunity to develop skills and strategies while
they try to achieve the game’s objectives. In contrast to
traditional educational methods, serious games are
more focused on the views and participation of the
learner, rather than the unidirectional guidance of the
trainer. A serious game itself will not make smokers
quit, but it will help to educate and guide those who
wish to end their habit.
The three main objectives for app development are
the following: (i) help the user record the progress of
the smoking cessation plan; (ii) inform and educate the
user about the problems of smoking and the improve-
ments to be anticipated from smoking cessation; (iii)
provide alternatives to the user for the times when he
or she particularly wants to smoke; for example, a
game might provide both entertainment (distraction)
and subliminal or indirect messages that can help
avoid the urge to smoke. The app will be adapted to
the specific stages of the cessation process (typically 6
months duration), and will adjust to the progress of
each participant.
To maximize the success of the intervention, a panel of
smoking cessation experts, young smokers and ex-smokers,
computer programmers, game developers, graphic de-
signers and education experts will be involved at the differ-
ent stages of the design and development of this app.
Although we expect many ideas to emerge during the de-
sign process, we envision several options that will be offered
to the participant to achieve these objectives:(1) Information about tobacco: answers to frequently
asked questions, advice, suggestions, definitions,
illustrations and images.(2) Private social network for study participants and
staff: participants can communicate with each other
to ask for help, share concerns, or offer help to
others. The project staff will also post information
about the process and offer helpful and supportive
messages through this network.
(3) Minigame(s): games designed specifically to
entertain and educate the participants.
(4) Progress registry: a visual representation of the
evolution of the participant’s health progress
through the treatment process.
Control group
Normal practice will be used in counselling controls, fol-
lowing the clinical practice guidelines of the Catalan
Health Institute.
Measures
During the recruitment visit, sociodemographic and an-
thropometric variables will be recorded: age, sex, educa-
tional level, employment, weight, height and blood
pressure. Social class will be categorized according to
the British Registrar General’s Social Classification [11].
Variables related to tobacco consumption also will be
recorded: number of cigarettes smoked per day, start
age, number of previous cessation attempts, longest
period of cessation, and presence of other smokers in
the family. The degree of nicotine dependence will be
measured by the Fageström test. Motivation to stop
smoking will be assessed by the Richmond test.
During follow-up visits, weight, height, and blood
pressure will again be measured. Participants will be
asked about their tobacco use and presence of with-
drawal symptoms (vehement desire to smoke, anxiety,
tension, nervousness, frustration, impatience, difficulty
in concentrating, hunger, drowsiness or difficulty in
sleeping, nightmares, headache, irritability/depression), and
CO in exhaled breath will be measured by carboximetry.
At each visit, the professional who provided smoking
cessation information (doctor or nurse) and any treat-
ment provided will be recorded. We will also record
the smoking cessation date (D-day) and the date of the
end of follow-up, either 12 months after D-day or date
lost to follow-up (D2). We will then calculate the
length of the follow-up period. (With these variables
the length of survival can be calculated: time interval
between start date of smoking cessation and relapse or
end of follow-up).
Tobacco abstinence will be confirmed by the level of
carbon monoxide (CO), set as 10 parts per million or
less, measured by carboximetry readings taken by trained
personnel.
The follow-up period will have the following end-
points: (1) 12 months after D-Day; (2) participant decides
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abandons participation; (2) participant is lost to follow-up,
provides no more information, and will be considered re-
lapsed as of that time point.Sample size/power calculation
To calculate sample size for each primary care centre,
the number of individuals in a simple randomized design
was multiplied by the design effect. Accepting an alpha
risk of 0.05 and a beta risk of 20% in a bilateral contrast,
222 subjects are required in each group to detect a dif-
ference of at least 5% (calculations based on EPIDAT v.
3.1). To calculate design effect, we estimated the intra-
cluster correlation coefficient (ICC) in clinical trials ran-
domized by primary care clusters, generally less than
0.05 [12], and as a cluster size. The average size is 20
with a design effect of 1.36. Assuming these values, the
definitive sample size for the study was set at 604 sub-
jects, randomised as described above.Statistical analysis
Analysis will be performed as intention to treat. At base-
line, the comparability of the intervention and control
groups will be assessed. Quantitative variables will be
described as the mean and standard deviation if they
have a normal distribution, or median and range, as ap-
propriate. Qualitative variables will be described as per-
centages and confidence intervals. Quantitative baseline
characteristics will be compared using Student t test.
Qualitative variables will use the Pearson chi squared test.
Multi-level multivariate survival analysis will include
two effects (fixed and random). The fixed component of
the adjusted model will include the group assignment
and a dummy variable for baseline and 12-month mea-
surements of the study variables, as well as interactions
between relevant variables. All significant covariates in
the bivariate analyses (p< 0.30) will be included in the
model. This strategy will sufficiently reduce the probabil-
ity of leaving relevant variables out of the model.
The primary response variable will be continued ab-
stinence at 12 months after beginning smoking cessation
(D-Day). We will use multiple techniques to deal with
missing values in covariates that are candidates for in-
clusion in multi-level models. The ’ICE” programme of
the STATA-10.1 package estimates missing values by
conditional logistic regression, concatenating them with
the variables that have complete values. As a convention,
a combination of 10 different estimates will be used that
includes the variability of these estimates. This will pre-
clude a loss of power due to missing data. In addition,
analysis of the models will be repeated to determine sen-
sitivity, using only the subjects for whom complete data
are available.Ethical aspects of the study
The study will be conducted in accordance with the
principles of the Helsinki Declaration, as revised and
updated, and will follow Spain’s best practice guidelines
(Buena Práctica Clínica). The protocol was evaluated
by our institute’s ethics committee (Comité Ético de
Investigación Clínica [CEIC], Institut d’Investigació en
Atenció Primària [IDIAP] Jordi Gol). Data confidentiality
will be protected under the Spanish law governing the
protection of personal data (Ley orgánica de Protección
de Datos de Carácter Personal (15/1999 13 December).
Discussion
The development of the proposed smartphone app, and
subsequent evaluation of its effectiveness in our popula-
tion, has the potential to contribute a useful tool for the
smoking cessation efforts of young adults, as well as pro-
viding information about the effectiveness of smoking
cessation interventions in a population that has not been
studied in our environment.
A limitation of the study is its open character. Both
patients and health care professionals will know that
they are involved in the intervention, which might create
a bias. The analysis will be blind, with no identifiers
available to the statistician that would indicate whether a
subject was assigned to the intervention or control
group. The study will use random clustering of primary
care centres to avoid the risk of contamination by taking
geography into account.
The randomization process is intended to result in a
balanced distribution of sociodemographic and cultural
characteristics between intervention and control groups,
both for doctors and nurses and for participating pa-
tients. To avoid contamination between the intervention
and control groups, the game and the app itself will only
be made available to the intervention group. Multivariate
analysis will be used to control for possible confounding
factors.
Another limitation is the difficulty of recruiting young
patients who want to stop smoking. The multicentre
study design, with 22 participating primary care centres
and a long (18-month) recruitment period, is intended
to ensure an adequate participant pool.
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